Richard Moffitt

 

Richard Moffitt, PhD     

Richard Moffitt, PhD, Associate Professor

Hematology and Medical Oncology / Biomedical Informatics
Winship Cancer Institute, Emory University
Affiliated Faculty, Department of Biomedical Informatics, Stony Brook University
Phone: (631) 638-2271
Email: Richard.Moffitt@stonybrookmedicine.edu

INTERESTS

Computational oncology, pancreatic cancer genomics and molecular subtyping, single-cell and spatial omics, real-world evidence from electronic health records, and Long COVID.
 
BIOGRAPHY
 
Dr. Richard Moffitt earned his PhD in bioengineering from the Wallace H. Coulter Department of Biomedical Engineering at the Georgia Institute of Technology and Emory University, and completed postdoctoral training at the Lineberger Comprehensive Cancer Center of the University of North Carolina at Chapel Hill. He served as Assistant Professor and graduate program director in the Department of Biomedical Informatics at Stony Brook University before joining Emory University, where he is Associate Professor in the Department of Hematology and Medical Oncology with a joint appointment in Biomedical Informatics at the Winship Cancer Institute.
 
RESEARCH
 
Dr. Moffitt’s research uses computational and omics-based approaches to understand cellular heterogeneity in cancer, with a focus on pancreatic ductal adenocarcinoma. His virtual microdissection work defined the widely used tumor and stroma molecular subtypes of pancreatic cancer, and his group developed PurIST, a clinically robust single-sample classifier for pancreatic tumor subtyping, along with pdacR, an open-source resource for exploration of pancreatic cancer gene expression data. He directs efforts to characterize tumor ecosystems using single-cell RNA sequencing, spatial sequencing, and spatial proteomics. As a leader within the National COVID Cohort Collaborative (N3C), he has also co-authored influential machine learning and electronic health record studies characterizing Long COVID.
 
SELECTED PUBLICATIONS

Full list: ORCID   

  1. Richard A. Moffitt, Raoud Marayati, Elizabeth L. Flate, Keith E. Volmar, Silvia G. Herrera Loeza, Katherine A. Hoadley, Naim U. Rashid, Lindsay A. Williams, et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nature Genetics, 47(10):1168-1178, 2015.
  2. Benjamin J. Raphael, Ralph H. Hruban, Andrew J. Aguirre, Richard A. Moffitt, Jen Jen Yeh, Chip Stewart, A. Gordon Robertson, Andrew D. Cherniack, et al. Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. Cancer Cell, 32(2):185-203.e13, 2017.
  3. Hervé Tiriac, Pascal Belleau, Dannielle D. Engle, Dennis Plenker, Astrid Deschênes, Tim D.D. Somerville, Fieke E. M. Froeling, Richard A. Burkhart, Richard A. Moffitt, et al. Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Cancer Discovery, 8(9):1112-1129, 2018.
  4. Naim U. Rashid, Xianlu L. Peng, Chong Jin, Richard A. Moffitt, Keith E. Volmar, Brian A. Belt, Roheena Z. Panni, Timothy M. Nywening, et al. Purity Independent Subtyping of Tumors (PurIST), A Clinically Robust, Single-sample Classifier for Tumor Subtyping in Pancreatic Cancer. Clinical Cancer Research, 26(1):82-92, 2019.
  5. Linara Gabitova-Cornell, Aizhan Surumbayeva, Suraj Peri, Janusz Franco‐Barraza, Diana Restifo, Nicole A. Weitz, Charline Ogier, Aaron R. Goldman, Richard A. Moffitt, et al. Cholesterol Pathway Inhibition Induces TGF-β Signaling to Promote Basal Differentiation in Pancreatic Cancer. Cancer Cell, 38(4):567-583.e11, 2020.
  6. Kyaw Aung, Sandra E. Fischer, Robert E. Denroche, Gun-Ho Jang, Anna Dodd, Sean Creighton, Bernadette Southwood, Sheng‐Ben Liang, Richard A. Moffitt, et al. Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial. Clinical Cancer Research, 24(6):1344-1354, 2017.
  7. Emily Pfaff, Andrew T. Girvin, Tellen D. Bennett, Abhishek Bhatia, Ian M. Brooks, Rachel Deer, Jonathan Dekermanjian, Sarah E. Jolley, Richard A. Moffitt, et al. Identifying who has long COVID in the USA: a machine learning approach using N3C data. The Lancet Digital Health, 4(7):e532-e541, 2022.
  8. Tellen D. Bennett, Richard A. Moffitt, Janos Hajagos, Benjamin Amor, Adit Anand, Mark M. Bissell, Katie R. Bradwell, Carolyn Bremer, et al. Clinical Characterization and Prediction of Clinical Severity of SARS-CoV-2 Infection Among US Adults Using Data From the US National COVID Cohort Collaborative. JAMA Network Open, 4(7):e2116901, 2021.
  9. Rachel Deer, Madeline Rock, Nicole Vasilevsky, Leigh Carmody, Halie M. Rando, Alfred Anzalone, Marc D. Basson, Tellen D. Bennett, Richard A. Moffitt, et al. Characterizing Long COVID: Deep Phenotype of a Complex Condition. EBioMedicine, 74:103722, 2021.
  10. Justin Reese, Hannah Blau, Elena Casiraghi, Timothy Bergquist, Johanna Loomba, Tiffany J. Callahan, Bryan Laraway, Corneliu Antonescu, Richard A. Moffitt, et al. Generalisable long COVID subtypes: findings from the NIH N3C and RECOVER programmes. EBioMedicine, 87:104413, 2022.
  11. Emily Pfaff, Charisse Madlock‐Brown, John M. Baratta, Abhishek Bhatia, Hannah Davis, Andrew T. Girvin, Elaine Hill, Elizabeth Kelly, Richard A. Moffitt, et al. Coding long COVID: characterizing a new disease through an ICD-10 lens. BMC Medicine, 21(1):58, 2023.
  12. M. Daniel Brannock, Robert Chew, Alexander Preiss, Emily Hadley, Signe Redfield, Julie A. McMurry, Peter Leese, Andrew T. Girvin, Richard A. Moffitt, et al. Long COVID risk and pre-COVID vaccination in an EHR-based cohort study from the RECOVER program. Nature Communications, 14(1):2914, 2023.
  13. Han Le, Rajarsi Gupta, Le Hou, Shahira Abousamra, Danielle Fassler, Luke A. Torre-Healy, Richard A. Moffitt, Tahsin Kurç, et al. Utilizing Automated Breast Cancer Detection to Identify Spatial Distributions of Tumor-Infiltrating Lymphocytes in Invasive Breast Cancer. American Journal Of Pathology, 190(7):1491-1504, 2020.